Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin Monotherapy in Type 2 Diabetes
NCT00621140Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2008
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Linagliptin 5 mg with Placebo (2 arms). Primary endpoint: HbA1c Change From Baseline at 24 weeks. Started Feb 2008; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00621140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00621140.